Physician profile
Yue Wang
NPI 1225143134
$8,768.46
in general payments reported to CMS, 2019-2025
27 companies · $992 in 2025
The $992 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $1,032 · 2021: $850 · 2022: $1,559 · 2023: $1,433 · 2024: $1,728 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,152.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,151.34 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $859.84 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $768.79 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $741.22 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $644.98 | 2019-2023 | |
| Novo Nordisk INC | $554.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $394.34 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $359.22 | 2019-2022 | |
| Abbvie INC. | $352.43 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $279.60 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $262.64 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $196.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $182.59 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.87 | 2025 | Caplyta |
| Pfizer INC. | $158.22 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $151.98 | 2022-2023 | |
| Gilead Sciences, INC. | $124.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.30 | 2022-2024 | Xifaxan |
| Astellas Pharma US INC | $85.00 | 2019 | |
| Aimmune Therapeutics, INC. | $60.95 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $45.34 | 2019-2020 | |
| Corcept Therapeutics | $38.93 | 2022 | |
| Alkermes, INC. | $21.94 | 2022 | |
| Exact Sciences Corporation | $16.67 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $14.92 | 2019 | |
| Amarin Pharma, INC. | $14.91 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.79 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yue Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.